merger build qualiti diagnost content progress de-
strive data top expect path superior phase
model updat order data
analyst certif import disclosur see
merger build qualiti diagnost content progress de-centr ivd kit need focu
perform rate ghdx base expect growth oncotyp dx breast franchis slow
benefit tailorx begin annual eventu shift ivd platform oncotyp dx breast oncotyp
dx would offer second leg growth particularli outsid us mani investor alreadi comment
correctli benefit purpos merger includ merg two respect manag team expertli
valid content believ may also meaning synergi merg compani acceler commerci
ivd kit de-centr test across expand menu either continu collabor ghdx
agreement biocarti futur ivd platform
strive data top expect path superior phase
cdtx report top line strive part data exceed expect numer higher day clinic
cure rate phase rezafungin dose vs caspofungin similar all-caus mortal
trend roughli reduct indetermin rate compar strive part manag provid
breakdown respons rate diseas sever ii difficult-to-treat invas candidiasi ic cdtx confirm
patient strive part gener sicker around ic patient vs strive part see three near-
term catalyst cdtx share ex us rezafungin partner ic subset analysi confirm rezafungin benefit sickest
patient remov balanc sheet overhang
last week featur earn pick posit datapoint evh expand
work passport spin subsidiari conif laid trump healthcar agenda includ
transpar interoper coordin vbps/aco drug price fix medicar better health
matern opioid kidney verma meanwhil blast public option tout consum choic less
govern competit mhn earn continu week wed
fri bmo full calendar page
model updat order data
adjust revenu ep model per order data releas today updat ep
guidanc trail order june flat organ fx compar expect return
late impact ep neutral lower segment profit off-set lower corpor expens
overal strong oper execut notabl autom solut report ep actual expect
cent prior /- guidanc reflect discret tax benefit adjust ep
lower revenu trend trim ep
